Open AccessOtilonium bromide in irritable bowel syndrome: A dose-ranging randomized double-blind placebo-controlled trial
Author(s) -
Danuta Chmielewska-Wilkoń,
Giorgio Reggiardo,
Colin Gerard Egan
Publication year - 2014
Publication title -
world journal of gastroenterology
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 1.427
H-Index - 155
eISSN - 2219-2840
pISSN - 1007-9327
DOI - 10.3748/wjg.v20.i34.12283
Subject(s) - placebo , medicine , irritable bowel syndrome , bloating , abdominal pain , gastroenterology , placebo controlled study , defecation , diarrhea , dose ranging study , double blind , alternative medicine , pathology
To examine the efficacy and safety of otilonium bromide (OB) in treatment-sensitive functional irritable bowel syndrome (IBS) clinical parameters.